Navigation Links
Drug Discovery Technologies, BCC Research
Date:9/6/2012

NEW YORK, Sept. 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Drug Discovery Technologies, BCC Research

http://www.reportlinker.com/p0958105/Drug-Discovery-Technologies-BCC-Research.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

INTRODUCTION

STUDY GOALS AND OBJECTIVES This market research report, Drug Discovery Technologies, provides an overview of the current state of the drug discovery market, existing platforms and products on the market, and detailed analysis of the competitive environments including new, potential venues for novel technologies and approaches. The study includes information about significant players in this field of study, trends and obstacles, and other information affecting development of new products, devices, and therapies in the drug discovery sector.REASONS FOR DOING THIS STUDY Drug discovery is one of the main sectors in the pharmaceutical industry. Drug development in general is a billion dollar industry and is highly dependent on its research and scientific advancement. Today, the process of drug discovery has become more systematic in comparison to the more physiological approaches in previous decades. In the current drug discovery market, the drug target is identified first, followed by a search for compounds or molecular entities that can inhibit or enhance its activity. Consequently, technology has a crucial impact on identification and validation of new drug candidates.

In general, the scientific and biotechnology community has seen many breakthrough technologies in the last decade. Surprisingly, there is a big gap between the initial introduction of new platforms and their further application and commercial success. Many analysts and industry insiders are trying to understand the reasons why, in spite of technological advancement, the pharmaceutical industry does not provide more successful drugs and why certain technologies fail to advance or accelerate the drug discovery process.

It is important to note that biological and pathological conditions are very complex. Therefore, in order to understand properly the effect of a technology or platform in drug discovery application, the market should be divided into main categories such as, for example, genomics or proteomics-based approaches and their related drug discovery technologies. Each sector has its novel trends and challenges that affect the drug discovery market in general and specific segments in particular.

Market participants vary among the different niches in the drug discovery industry. There is also a clear division between technology developers, manufacturer/ suppliers, and biotech companies. Each type of market participant has a different business strategy and is affected differently by positive or negative drivers discussed in this report.

In summary, this report will highlight the main aspects, sectors, and trends in the drug discovery technologies market, the major market participants, and the current and future trends in each sector. Drivers and challenges in each segment of the industry will be discussed in detail including forecasts for the next five years.

SCOPE AND FORMAT This report represents a current and important business tool to evaluate new commercial opportunities in the drug discovery technology market. The geographic scope of this study covers the U.S., Europe, and companies worldwide. This market is complex and consists of a number of sectors, each affected differently by scientific and technological development. The report identifies main positive and negative factors in each sector and forecasts further trends, products, and technologies in every category of the industry.METHODOLOGY AND INFORMATION SOURCES Both primary and secondary research methodologies were used in preparing this report. The research methodology was more qualitative than quantitative in nature and employed a triangulating approach, which aids validity. Initially, a comprehensive and exhaustive search of the literature on drug discovery and already-marketed products was conducted. These secondary sources included drug discovery and science-related journals, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. A patent search and analysis was also conducted.

In a second phase, a series of semi-structured interviews was conducted with company representatives, bench scientists, marketing representatives, and other personnel at biotech and pharmaceutical companies. Other resources included academic institutions and technology and consulting companies. These were a rich source of data. Subsequent analysis of the documents and interview notes was iterative.

INTENDED AUDIENCE

This report is intended for business development professionals, entrepreneurs and other investment groups in order to fully understand and properly evaluate each segment in the drug discovery technology market. It provides a company's corporate development department with new insight into competitors' positions and reveals new opportunities otherwise overlooked or less known to the public.

ANALYST CREDENTIALS

Dr. Marianna Tcherpakov has more than eight years of experience as a bench scientist specializing in the area of biochemistry, cell biology, and industrial assay development. She has contributed to a number of scientific publications and holds several patents. She has expertise as an assay development scientist and is familiar with different research field trends and likely future developments.

TABLE OF CONTENTS CHAPTER ONE: INTRODUCTION 1

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THIS STUDY 1

SCOPE AND FORMAT 2

METHODOLOGY AND INFORMATION SOURCES 2

INTENDED AUDIENCE 2

ANALYST CREDENTIALS 3

RELATED REPORTS 3

BCC ON-LINE SERVICES 3

DISCLAIMER 4

CHAPTER TWO: SUMMARY 5

SUMMARY 5

SUMMARY TABLE GLOBAL MARKET FOR DRUG DISCOVERY

TECHNOLOGIES AND PRODUCTS, THROUGH 2017 ($ BILLIONS) 6

SUMMARY FIGURE GLOBAL MARKET FOR DRUG DISCOVERY

TECHNOLOGIES AND PRODUCTS, 2011–2017 ($ BILLIONS) 7

CHAPTER THREE: OVERVIEW 8

INTRODUCTION 8

INTRODUCTION (CONTINUED) 9

PRECLINICAL TESTING AND SUBMISSION OF AN

INVESTIGATIONAL NEW DRUG 10

CLINICAL TRIALS 11

SUBMISSION OF NEW DRUG APPLICATION OR

BIOLOGICAL LICENSING APPLICATION 12

POST–FOOD AND DRUG ADMINISTRATION APPROVAL 13

IMPACT OF GOVERNMENT REGULATIONS AND REGULATORY

APPROVALS ON THE DRUG DISCOVERY INDUSTRY 14

NEW DRUG APPROVALS 14

TABLE 1 NEW MOLECULAR ENTITY (NME) APPLICATIONS

VERSUS APPROVAL BY THE FDA, 2006–2010 14

FIGURE 1 NEW MOLECULAR ENTITY (NME) APPLICATIONS

VERSUS APPROVAL BY THE FDA, 2006–2010 14

New Drug Approvals (Continued) 15

TIMELINE AND COSTS 16

FIGURE 2 TIMELINE FOR DRUG DEVELOPMENT PROCESS 16

TABLE 2 FACTS ABOUT DRUG DISCOVERY AND DEVELOPMENT

FOR 2010 17

TABLE 3 R&D SPENDING FOR DRUG DISCOVERY IN

BIOPHARMACEUTICAL COMPANIES, 2008–2012 ($ MILLIONS) 17

IMPORTANCE OF TECHNOLOGY IN DRUG DISCOVERY 18

MARKET LANDSCAPE IN THE DRUG DISCOVERY SECTOR 19

TABLE 4 FDA-APPROVED DRUGS FOR SALE IN THE U S 2001-2011 20

TABLE 5 GLOBAL PHARMACEUTICAL MARKET VALUE, THROUGH

2017 ($ BILLIONS) 21

MARKET PARTICIPANTS IN THE DRUG DISCOVERY

SECTOR 21

TABLE 6 TOP GLOBAL PHARMACEUTICAL CORPORATION

RANKING, 2009 22

TABLE 7 NUMBER OF DEALS AND THEIR VALUE IN THE

PHARMACEUTICAL INDUSTRY IN DIFFERENT COUNTRIES,

2010 23

PATENTS AND DRUG DISCOVERY TECHNOLOGY 23

PATENTS AND DRUG DISCOVERY … (CONTINUED) 24

PATENTS AND DRUG DISCOVERY … (CONTINUED) 25

TABLE 8 PATENT APPLICATION IN DRUG DISCOVERY FROM

MARCH 2012 26

TABLE 8 (CONTINUED) 27

CHAPTER FOUR: GENOMICS RESEARCH AND DRUG DISCOVERY

TECHNOLOGIES 28

OVERVIEW 28

GENOMICS STUDIES AS A PLATFORM FOR DRUG DISCOVERY

TECHNOLOGIES 29

POLYMERASE CHAIN REACTION TECHNOLOGY AS BASIS

FOR DRUG DISCOVERY 30

TABLE 9 GLOBAL REAL-TIME POLYMERASE CHAIN REACTION

MARKET, THROUGH 2017 ($ BILLIONS) 31

DNA MICROARRAYS AND DRUG DEVELOPMENT 32

DNA Microarrays and Drug Development (Continued) 33

TABLE 10 GLOBAL MARKET FOR DNA MICROARRAYS, THROUGH

2017 ($ BILLIONS) 34

RNA RESEARCH AS DRUG DISCOVERY PLATFORM FOR

NEW TECHNOLOGIES DEVELOPMENT 35

RNA Research as Drug Discovery … (Continued) 36

RNA Interference as Approach to Drug Discovery 37

TABLE 11 GLOBAL RNA INTERFERENCE MARKET, THROUGH 2017

($ MILLIONS) 38

Market Participants in the Drug Discovery Sector 38

Market Participants … (Continued) 39

NEXT-GENERATION SEQUENCING AS A TECHNOLOGY

FOR DRUG DISCOVERY RESEARCH 40

Next-Generation Sequencing … (Continued) 41

TABLE 12 GLOBAL NEXT-GENERATION SEQUENCING MARKET,

THROUGH 2017 ($ MILLIONS) 42

Next-Generation Sequencing Market Participants 43

Next-Generation … (Continued) 44

TABLE 13 NEXT-GENERATION SEQUENCING MARKET SHARES BY

COMPANY, 2012 (%) 45

EPIGENETICS APPROACH AS A PLATFORM FOR DRUG

DISCOVERY 45

DNA METHYLATION 46

HISTONE METHYLATIONS AND MODIFICATIONS 47

TABLE 14 PERCENTAGE OF COMMERCIAL KITS GENERALLY

PURCHASED FOR EPIGENETIC RESEARCH (%) 48

Market Evaluation for Drug Discovery in Epigenetics

Research 48

TABLE 15 GLOBAL MARKET FOR RESEARCH AND DRUG

DISCOVERY IN EPIGENTICS, THROUGH 2017 ($ BILLIONS) 49

TABLE 16 SALES OF FOUR EPIGENETIC DRUGS, 2009–2011 ($

MILLIONS) 50

SUMMARY AND EVALUATION OF GENOMICS-BASED DRUG

DISCOVERY TECHNOLOGY MARKET 51

TABLE 17 GLOBAL MARKET FOR GENOMICS-BASED DRUG

DISCOVERY PLATFORMS, THROUGH 2017 ($ BILLIONS) 51

CHAPTER FIVE: PROTEOMICS RESEARCH AS A DRUG DISCOVERY

TECHNOLOGY AND PLATFORM 52

OVERVIEW 52

PROTEOMICS TECHNOLOGIES THE IN DRUG DISCOVERY

MARKET 53

PROTEIN ISOLATION AND IDENTIFICATION

TECHNOLOGY FOR BIOMARKER OR DRUG TARGET

DISCOVERY 53

Size Exclusion Chromatography 54

Separation Based on Charge or Hydrophobicity 54

Affinity Chromatography 55

Immunoaffinity Chromatography 55

High-Performance Liquid Chromatography as One of the

Main Technologies in Proteomics Drug Discovery 55

High-Performance Liquid (Continued) 56

Sample Injectors 57

Pumps 57

Columns 57

TABLE 18 GLOBAL HIGH-PERFORMANCE (OR HIGH-PRESSURE)

LIQUID CHROMATOGRAPHY (HPLC) MARKET, THROUGH 2017 ($

BILLIONS) 58

TABLE 19 PERCENTAGE OF CUSTOMER DISTRIBUTION IN

COLUMN SEPARATION MARKET IN 2011 59

PROTEIN IDENTIFICATION AND CHARACTERIZATION

TECHNIQUES IN PROTEOMICS DRUG DISCOVERY 59

Mass Spectrometry and the Drug Discovery Sector 59

Mass Spectrometry Instruments 60

Ionization Procedure 60

Matrix-Assisted Laser Desorption/Ionization

(MALDI) 61

Electrospray Ionization (ESI) 61

Atmospheric Pressure Chemical Ionization

(APCI) 61

Mass Analyzers 62

Quadrupole 62

Time-of-Flight Mass Spectrometry 62

Quadrupole—Time-of-Flight (Q-TOF) 63

Ion Trap Mass Spectroscopy 63

Orbitrap 64

TABLE 20 EXAMPLES OF MASS SPECTROMETRY ANALYZERS

USED IN THE PHARMACEUTICAL INDUSTRY 65

Market Overview for Mass Spectrometry 65

TABLE 21 GLOBAL MASS SPECTROMETRY MARKET, THROUGH

2017 ($ BILLIONS) 65

Main Players in Mass Spectrometry Industry 66

NMR (NUCLEAR MAGNETIC RESONANCE) APPROACH IN

PROTEOMICS DRUG DISCOVERY 67

TABLE 22 PERCENTAGE OF TOTAL NUCLEAR MAGNETIC

RESONANCE (NMR) APPLICATIONS IN VARIOUS SECTORS (%) 68

TABLE 23 GLOBAL NUCLEAR MAGNETIC RESONANCE (NMR)

MARKET, THROUGH 2017 ($ MILLIONS) 68

X-RAY CRYSTALLOGRAPHY 69

X-Ray Crystallography (Continued) 70

TWO-DIMENSIONAL GEL APPROACH AS A TECHNOLOGY

IN PROTEOMICS DRUG DISCOVERY 71

TABLE 24 GLOBAL MARKET FOR TWO-DIMENSIONAL (2D) GEL

ANALYSIS, THROUGH 2017 ($ MILLIONS) 71

Two-Dimensional Gel Approach … (Continued) 72

PROTEIN-PROTEIN INTERACTION IDENTIFICATION

TECHNIQUES IN DRUG DISCOVERY 73

PROTEIN MICROARRAYS AS PART OF A DRUG

DISCOVERY PLATFORM 74

TABLE 25 GLOBAL PROTEIN CHIP MARKET, THROUGH 2017 ($

MILLIONS) 75

Protein Microarrays …(Continued) 76

PROTEOMICS-BASED DRUG DISCOVERY MARKET LANDSCAPE 77

TABLE 26 PROTEOMICS MARKET PARTICIPANTS BY INDUSTRY

SEGMENT 77

PROTEOMICS-BASED … (CONTINUED) 78

TABLE 27 GLOBAL PROTEOMICS DRUG DISCOVERY TECHNOLOGY

MARKET, THROUGH 2017 ($ BILLIONS) 79

PROTEOMICS-BASED … (CONTINUED) 80

CHAPTER SIX: METABOLOMICS AS DRUG DISCOVERY PLATFORM 81

OVERVIEW 81

GENERAL TECHNIQUES AND METHODS FOR

METABOLITE PROFILING 81

METABOLOMICS APPLICATIONS AND DRUG DISCOVERY 82

Market Evaluation for Metabolomic Application 83

TABLE 28 GLOBAL MARKET FOR METABOLOMICS APPLICATIONS,

THROUGH 2017 ($ MILLIONS) 84

NEW TECHNOLOGICAL PLATFORMS 84

FURTHER DEVELOPMENT OF BIOINFORMATICS AND

CHEMOMETRICS STUDIES 84

Market Participants in the Metabolomics Industry 85

TABLE 29 SELECT MARKET PARTICIPANTS IN THE

METABOLOMICS MARKET 85

Market Participants … (Continued) 86

Market Participants … (Continued) 87

CHAPTER SEVEN: HIGH-THROUGHPUT SCREENING IN DRUG

DISCOVERY 88

OVERVIEW 88

HIGH-CONTENT SCREENING AS HIGH-IMPACT SECTOR

OF THE HIGH-THROUGHPUT SCREENING INDUSTRY 89

High-content Screening … (Continued) 90

TABLE 30 GLOBAL MARKET FOR HIGH-THROUGHPUT

SCREENING APPROACH IN DRUG DISCOVERY, THROUGH 2017

($ BILLIONS) 91

Positive and Negative Drivers Affecting the High-

Throughput Screening Market for Drug Discovery 91

TABLE 31 GEOGRAPHICAL DISTRIBUTION OF HIGHTHROUGHPUT

SCREENING MARKET USERS FOR 2012 (%) 92

TABLE 32 EFFECT OF NANODROP TECHNOLOGY ON COSTS IN

TYPICAL LUMINESCENCE ASSAYS 93

TABLE 33 MAIN MARKET PROVIDERS IN HIGH-THROUGHPUT

SCREENING IN 2012 94

CHAPTER EIGHT: BIOINFORMATICS AS A PLATFORM FOR DRUG

DISCOVERY 95

OVERVIEW 95

OVERVIEW (CONTINUED) 96

TABLE 34 GLOBAL MARKET FOR BIOINFORMATICS PRODUCTS

THROUGH 2017 ($ BILLIONS) 97

HARDWARE, INSTRUMENTS AND SOFTWARE

DEVELOPMENT 97

DATABASE AND CONTENT PRODUCTS AND SERVICES 97

DATA MANAGEMENT AND STORAGE 98

MARKET LANDSCAPE IN BIOINFORMATICS INDUSTRY FOR

DRUG DISCOVERY 98

TABLE 35 FREE MAJOR ONLINE SOURCES OF GENOMIC AND

PROTEOMIC INFORMATION 99

TABLE 36 EXAMPLE OF ANNUAL REVENUES OF SOME MARKET

PARTICIPANTS IN THE BIOINFORMATICS MARKET FOR DRUG

DISCOVERY, 2009-2011 ($ MILLIONS) 100

MARKET LANDSCAPE IN … (CONTINUED) 101

CHAPTER NINE: CELLULAR ASSAYS AS TECHNOLOGY AND

PLATFORM FOR DRUG DISCOVERY 102

OVERVIEW 102

TABLE 37 GLOBAL SHARES OF CELL-BASED ASSAYS MARKET BY

CATEGORY, 2012 (%) 102

G-PROTEIN COUPLED RECEPTORS (GPCR) AS A TARGET

FOR CELL-BASED ASSAY DEVELOPMENT IN THE

DRUG DISCOVERY INDUSTRY 103

ION CHANNELS AS TARGETS FOR CELL-BASED ASSAY

DEVELOPMENT 104

Cell-Based Kinase Assays 104

Cell-Based … (Continued) 105

TABLE 38 GLOBAL MARKET SHARES OF CELL BIOLOGY

REAGENTS BY PRODUCT CATEGORY (%) 106

TABLE 39 GLOBAL MARKET FOR CELL BIOLOGY REAGENTS,

THROUGH 2017 ($ BILLIONS) 106

Light Microscopy 107

Fluorescent Microscopy 107

Confocal Microscopy 107

Electron Microscopy 108

TABLE 40 GLOBAL MARKET FOR CELL-BASED ASSAYS FOR DRUG

DISCOVERY, THROUGH 2017 ($ BILLIONS) 108

MARKET PARTICIPANTS IN THE CELL-BASED DRUG

DISCOVERY MARKET 109

MARKET PARTICIPANTS IN THE … (CONTINUED) 110

TABLE 41 EXAMPLES OF STEM CELL RESEARCH ASPECTS THAT

REQUIRE DEVELOPMENT OF SPECIFIC RESEARCH TOOLS,

ASSAYS AND SERVICES 111

TABLE 42 SELECT REAGENTS PROVIDERS FOR STEM CELL

RESEARCH AND DRUG DISCOVERY 112

TABLE 42 (CONTINUED) 113

TABLE 43 EXAMPLES OF STEM CELL POLICIES IN DIFFERENT

COUNTIES 114

TABLE 43 (CONTINUED) 115

CHAPTER TEN: COMBINATORIAL AND MEDICINAL CHEMISTRY AS A

TECHNOLOGY AND PLATFORM FOR DRUG DISCOVERY 116

OVERVIEW 116

OVERVIEW (CONTINUED) 117

COMBINATORIAL CHEMISTRY TECHNOLOGY 118

COMBINATORIAL CHEMISTRY …(CONTINUED) 119

NATURE AS A SOURCE OF DRUGS 120

MARKET ESTIMATES FOR COMBINATORIAL CHEMISTRY 120

TABLE 44 GLOBAL MARKET FOR COMBINATORIAL CHEMISTRY IN

DRUG DISCOVERY, THROUGH 2017 ($ BILLIONS) 121

CHAPTER ELEVEN: BIOANALYTICAL INSTRUMENTS IN THE DRUG

DISCOVERY SECTOR 122

OVERVIEW 122

TABLE 45 GLOBAL MARKET FOR BIOANALYTICAL INSTRUMENTS

IN DRUG DISCOVERY, THROUGH 2017 ($ BILLIONS) 123

CHAPTER TWELVE: NOVEL AND INNOVATIVE TRENDS IN DRUG

DISCOVERY TECHNOLOGY DEVELOPMENT 124

SYNTHETIC BIOLOGY IN DRUG DISCOVERY 124

SYSTEMS BIOLOGY AS DRUG DISCOVERY PLATFORM 125

TABLE 46 ESTIMATED VALUE OF SYSTEMS BIOLOGY MARKET,

THROUGH 2017 ($ MILLIONS) 126

SYSTEMS BIOLOGY AS DRUG … (CONTINUED) 127

NANOTECHNOLOGY AS A NEW ESSENTIAL TREND IN DRUG

DISCOVERY AND DEVELOPMENT 128

TABLE 47 MEDICAL PRODUCT EXAMPLES WITH FUNCTIONAL

NANOTECH COMPONENTS 129

TABLE 47 (CONTINUED) 130

TABLE 48 GLOBAL MARKET FOR NANOMEDICINE PRODUCTS,

THROUGH 2017 ($ BILLIONS) 130

NANOTECHNOLOGY AS A NEW … (CONTINUED) 131

CHAPTER THIRTEEN: MARKET SUMMARY 132

MARKET SUMMARY 132

MARKET SUMMARY (CONTINUED) 133

TABLE 49 GLOBAL MARKET FOR DRUG DISCOVERY

TECHNOLOGIES AND PRODUCTS, THROUGH 2017 ($ BILLIONS) 134

FIGURE 3 GLOBAL MARKET FOR DRUG DISCOVERY

TECHNOLOGIES AND PRODUCTS, 2011–2017 ($ BILLIONS) 134

MARKET SUMMARY (CONTINUED) 135

CHAPTER FOURTEEN: COMPANY PROFILES 136

ACCELRYS INC 136

AGILENT TECHNOLOGIES 137

ILLUMINA INC 138

ISIS PHARMACEUTICALS 139

LUMINEX CORP 140

WATERS CORP 141

WATERS CORP (CONTINUED) 142

APPENDIX: LIST OF SELECT COMPANIES REPRESENTING THE

DRUG DISCOVERY INDUSTRY 143

ACTIVE MOTIF 143

ADVANCED CELL TECHNOLOGY INC 143

AFFYMETRIX 143

ALDAGEN INC 143

ALNYLAM PHARMACEUTICALS 143

ASTRAZENECA PHARMACEUTICAL LP 144

AVIVA BIOSCIENCES CORP 144

AURORA BIOMED INC 144

BD BIOSCIENCES 144

BECKMAN COULTER INC 144

BIO-RAD LABORATORIES 144

BIOMYX TECHNOLOGY 145

BIOVISION 145

BRUKER CORP 145

BTX INSTRUMENT DIVISION 145

CALIPER LIFE SCIENCES 145

CAPRICOR INC 145

CELL BIOSCIENCES INC 146

CELLCENTRIC LTD 146

CELGENE CORP 146

CEPHEID 146

CERES NANOSCIENCES 146

CHEMBRIDGE CORP 146

CHEMDIV 147

CHENOMX 147

CLONTECH LABORATORIES 147

COMPLETE GENOMICS INC 147

COMPUGEN LTD 147

DEVELOGEN AG 147

DIGILAB INC 148

ECHELON BIOSCIENCES INC 148

EMD4BIOSCIENCES 148

EMERALD BIOSYSTEMS 148

EPIGENTEK GROUP INC 148

EXIQON A/S 148

EVOTEC INC 149

FLUIDIGM 149

GAMIDA CELL LTD 149

GE HEALTHCARE U K LTD 149

GENECRAFT 149

GENOMATICA 149

GILSON INC 150

HIGH THROUGHPUT GENOMICS INC 150

F HOFFMAN-LA ROCHE AG 150

KINEXUS BIOINFORMATICS CORP 150

LI-COR 150

LIGON DISCOVERY 150

LIFE TECHNOLOGIES CORP 151

MARINA BIOTECH 151

MAXCYTE INC 151

METABOLON INC 151

MILLIPORE (EMD GROUP) 151

MOLECULAR DEVICES INC 151

NEURALSTEM 152

NEW ENGLAND BIOLABS 152

NEXTGEN SCIENCES INC 152

OSIRIS THERAPEUTICS INC 152

PERKIN-ELMER 152

PLURISTEM THERAPEUTICS INC 152

PROMEGA CORP 153

PROTAGEN AG 153

PROTEA BIOSCIENCES INC 153

PROTEIN DISCOVERY INC 153

PROTEOME SYSTEMS 153

QIAGEN 153

R&D SYSTEMS INC 154

SHIMADZU CORP 154

SIGMA-ALDRICH 154

STEMGENT 154

TECAN GROUP LTD 154

THERMO FISHER SCIENTIFIC INC 154

VIACYTE 155

To order this report:Drug_Discovery_and_Development Industry: Drug Discovery Technologies, BCC Research

Nicolas Bombourg

Reportlinker

Email: nicolasbombourg@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Antigen Discovery Inc. Awarded Phase I SBIR Grant to Develop a Fully Integrated Microfluidic Point of Care Diagnostic Device
2. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
3. Zenobia Therapeutics Announce A Partnership With The Alzheimers Drug Discovery Foundation
4. Antigen Discovery, Inc. Awarded Phase II SBIR Grant to Identify Biomarkers Associated with Protection against Malaria
5. Omeros Announces Discovery in MASP-2 Program
6. Discovery Labs Receives US Patent for Method to Promote Mucus Clearance with Pulmonary Surfactant
7. Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
8. Global Information, Inc. Announces New Market Forecasts For Drug Discovery Industry as it Emerges from Recession
9. Tetra Discovery Partners Receives Major NIH Award To Develop New Alzheimers Drug
10. AMRI Further Expands Discovery Capabilities in India
11. Drug Discovery Technologies Market Soars to $79 billion by 2017, Driven by Innovations in Pipeline and Tools Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  CVS Health (NYSE: ... people living in Santa Clara County, CA ... B on the Santa Clara University campus. CVS Pharmacy ... to protect patients against the disease. Students at Santa ... to get vaccinated. In addition, anyone who has had ...
(Date:2/10/2016)... , Feb. 10, 2016  Oxis International Inc. (OTC/QB: ... OXS-1550, was described as a "clinical trial triumph" after ... went into complete cancer remission. Daniel ... Minnesota Masonic Cancer Center. --> Daniel ... Minnesota Masonic Cancer Center. --> An ...
(Date:2/10/2016)... 2016  LexisNexis® Risk Solutions, a leading provider ... launch of LexisNexis Provider Performance Monitor , ... and optimize the quality and efficiency of provider ... scores. By measuring provider performance through Provider Performance ... better outcomes, improve the patient experience and reduce ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact Phyllis ... Pioneering book "Better with Age: The Ultimate Guide to Brain Training" by award-winning author ... memory. The book’s publication date is March 16, 2016. A free review copy ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... digital self-scheduling readily available to physicians. The integration will enable Allscripts users ... select appointments via Everseat’s free mobile app. , The partnership gives Everseat substantial ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... Workrite ... and most versatile series of monitor mounts ever. , “Our goal was to ... and easy to install system that we have ever created.” said Darren Hulsey, Product ...
(Date:2/10/2016)... ... ... Anxiety of older Americans over steep cost increases of prescription drugs is at ... to The Senior Citizens League (TSCL). Since last fall, TSCL has ... costs. “The implications are chilling, particularly for people with chronic health problems,” says ...
(Date:2/10/2016)... ... February 09, 2016 , ... Ross A. Clevens, MD, ... to welcome a new addition to their growing practice. Beginning this month, Teresa ... nurse practitioner performing cosmetic procedures including injectables, fillers and laser treatments. ...
Breaking Medicine News(10 mins):